Demand for security of pharma & medical supplies post-COVID drives open standards

Demand from governments and health organisations for greater assurances on the integrity and reliability of pharmaceutical and medical products to treat COVID-19 has prompted advanco, a leader in product serialisation tracking software, to accelerate its plans for growth across global markets.

Common standards across pharmaceuticals industry are being rolled out now by the industry body OpenSCS. However, advanco, which is a founder member of Open-SCS, already offers serialisation solutions compliant with the new open industry standards – and is the only software provider currently doing so.

Rising demand to authenticate medicines and essential products looks set to drive the global market for track and trace software solutions from around $2 billion last year to almost $9 billion by 2025.

Parabellum Investments, a privately-owned international investment firm specialising in mid-market companies, acquired advanco last month, with plans to help the company expand in global markets.

“We see great scope for advanco to consolidate its leadership globally in the tracking of critical medicines and other pharmaceutical products in the aftermath of COVID-19, and want to help the business take best advantage of the shift to open standards,” said Rami Cassis, founder and CEO of Parabellum Investments.

Alf Goebel, CEO of advanco, added: “Global pharmaceuticals companies need systems which support open industry standards because, in the wake of COVID-19, governments are demanding assurances that critical medicines and medical products can be sourced locally using ingredients or components from guaranteed sources.

“advanco is currently in pole position to help deliver this, being the first software vendor to implement the open protocol and, post COVID, the benefits should be substantial.

“Open interfaces are both easier and cheaper for manufacturers and should help them be more agile and flexible across their supply chains as the situation continues to develop in response to this pandemic.”

Many countries already have regulations in place to prevent, detect and respond to substandard, unregistered or unlicensed medical products – which include a requirement to serialise individual medicines so they can be tracked and authenticated.

In the wake of COVID-19, governments in the US and elsewhere are looking to go further, also requiring manufacturers to give evidence of local sourcing for critical products – and product serialization software will also be essential to evidence this.

Open standards will be vital to stem a potential tide of fake drugs and vaccines to treat COVID-19 as countries around the world struggle to recover after the pandemic. Fake drugs are already a major challenge, accounting for around 10% of medicines in developing countries, according to the World Health Organisation and hundreds of thousands of unnecessary deaths.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...